Procoagulant state, inflammation, and endothelial dysfunction have been documented in metabolic syndrome. Endothelial dysfunction is a strong predictor of cardiovascular events. Studies on the association of thrombin-activatable fibrinolysis inhibitor and thrombosis are still controversial, but substantial evidence suggests that increased thrombin-activatable fibrinolysis inhibitor or thrombin-activatable fibrinolysis inhibits or protects against arterial thrombosis. This study aimed to assess concomitantly the effects of fenofibrate therapy on thrombin-activatable fibrinolysis inhibitor concentrations and endothelial functions in patients with metabolic syndrome. Twenty-five patients (16 women; mean age 50.4 +/- 7.0) were enrolled in the study. Plasma thrombin-activatable fibrinolysis inhibitor, C-reactive protein, and fibrinogen levels were measured before fenofibrate administration and after 8 weeks of fenofibrate treatment. Endothelial function was assessed by endothelial-dependent flow-mediated dilatation from brachial artery. Pretreatment (baseline) thrombin-activatable fibrinolysis inhibitor level was 52.3 (1.2-119.7) decreasing to 7.7 (0.9-51.2; P < 0.001) after 8 weeks of fibrate treatment. Endothelial functions, which were measured with flow-mediated dilatation, were significantly improved after treatment (mean flow-mediated dilatation was 6.76 +/- 2.21 at baseline and 10.66 +/- 1.17% after 8 week of fenofibrate treatment, P < 0.001). Fenofibrate decreases thrombin-activatable fibrinolysis inhibitor levels and improves endothelial function in metabolic syndrome and, thus, suggests a potential for protection against cardiovascular effects. Further studies are warranted to confirm the effects of fibrates on thrombin-activatable fibrinolysis inhibitor and for conclusive evidence on the association between thrombin-activatable fibrinolysis inhibitor and thrombosis.
This study was performed to investigate the antimicrobial effect of propolis from Hakkari province of Turkey and its chemical content by Gas Chromatography-Mass Spectroscopy. In vitro inhibitory activity of propolis was studied by the disc diffusion method against six gram positive, three gram negative bacteria and one yeast like fungi. As a result of chemical analysis, the total flavonoid ratio of the propolis sample was found to be higher than the other compound groups. Pinostrobin chalcone, pinocembrin and chrysin were identified as major flavonoids. Also, all microorganisms tested were susceptible to the propolis extract except for Klebsiella pneumoniae. Minimum inhibition concentration (MIC) values were determined by microbroth dilution assay. MIC values against microorganisms ranged from 25 to 200 µg/mL. Antimicrobial susceptibility test results showed that inhibitory effect our propolis sample was somewhat weaker than ampicillin, but it had a broader spectrum.
Propolis is a resinous substance produced by honey bees from various plants they visit. Sixty-four propolis samples were collected from different localities of four districts (Merkez, Yüksekova, Şemdinli, and Çukurca) in Hakkari territory. Ethanol extracts of the propolis samples were prepared, and their chemical contents were determined by gas chromatography-mass spectroscopy (GC-MS). Flavonoids were generally found in a high concentration in Şemdinli samples of Turkey. Twenty-seven coumarins were identified in the 28 propolis samples among studied 64 ones. Except suberosin, the coumarins were never reported before in any propolis sample with Turkish origin. The propolis samples belonging to Yüksekova were found to be richer in coumarins than the others, and the most richest one among the Yüksekova apiaries, was found to be Akocak sample (Y2) with 41.99% total yield, followed by Akçalı sample (Y5) (30.86%). This is a first comprehensive and original report about the chemical profile of propolis samples from Hakkari. The propolis samples from Hakkari exhibited a chemical content rich in flavonoids including coumarins and furocoumarins.
Introduction Sweet cherry (Prunus avium L.), one of the most consumed fruits in the world, is rich in phenolic and especially anthocyanin content. Objective The aim of this study was to evaluate the phenolic properties of 11 different sweet cherry genotypes collected from Giresun, Turkey. Methods Total phenol, flavonoid, anthocyanin and antioxidant properties were observed spectrophotometrically in three different extraction (conventional, microwave‐assisted and ultrasound‐assisted) processes. Major phenolic, anthocyanin and antioxidant structures were visually assessed by high‐performance thin layer chromatography (HPTLC). Various phenolics in its structure were determined by liquid chromatography–tandem mass spectrometry (LC–MS/MS). Results T2 and E5 genotypes had the highest content in terms of total phenol, flavonoid, anthocyanin and antioxidant activity. In HPTLC, cherry samples contained high levels of chlorogenic acid, neochlorogenic acid, p‐coumaroylquinic acid, rutin and cyanidin‐3 rutinoside. Among the phenolics examined in the LC–MS/MS method, the major compounds in the structure of cherry were found to be chlorogenic acid, rutin and catechin. The T2 genotype had higher phenolics than the other cherry samples (chlorogenic acid 19.3 mg/100 g; catechin; 3.8 mg/100 g; rutin 33.1 mg/100 g). Conclusion As a result, T2 and E5 genotypes had higher phenolic and antioxidant activity compared to other genotypes and commercial cultivars. It can be said that the antioxidant contents of these genotypes are due to the high anthocyanin amount in their structures. In addition, T2 genotype contained more major phenolics than other cherries. In the next stage, it is recommended to carry out studies on the cultivation of these two varieties.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.